Diethylstilbestrol revisited in advanced breast cancer management

1990 ◽  
Vol 18 (4) ◽  
pp. 317-320 ◽  
Author(s):  
Michael J. Boyer ◽  
Martin H. N. Tattersall
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Cancer Management ◽  
Breast Cancer Management

scholarly journals Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations

2015 ◽  
Vol 11 (16) ◽  
pp. 2251-2254 ◽  
Author(s):  
Lucia Del Mastro ◽  
Marina Cazzaniga ◽  
Paolo Solidoro ◽  
Daniele Generali ◽  
Giulia Bianchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Hormone Receptor ◽  
Advanced Breast ◽  
Cancer Management ◽  
Hormone Receptor Positive ◽  
Breast Cancer Management

Molecular Testing in Breast Cancer

2019 ◽  
pp. e1-e7 ◽  
Author(s):  
Jennifer K. Litton ◽  
Harold J. Burstein ◽  
Nicholas C. Turner
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Hereditary Cancer ◽  
Standard Of Care ◽  
Genomic Variation ◽  
Advanced Breast ◽  
Hereditary Cancer Syndrome ◽  
Molecular Testing ◽  
Breast Cancers ◽  
Cancer Management

Molecular testing for genetic and genomic variation has become an integral part of breast cancer management. Patients with a family history of breast cancer or other tumors, bilateral breast cancers, or early-onset breast cancers warrant genetic testing to determine whether a hereditary cancer syndrome is present. The availability of PARP inhibitors—drugs that are selectively active in BRCA1/2-associated breast cancers—has created the need for hereditary cancer testing for all patients diagnosed with advanced breast cancer. Tumor genomic profiling is the standard of care for many types of malignancies and is becoming increasingly important in the management of advanced breast cancer. Targetable mutations in advanced breast cancer include PIK3CA, HER2, and rare instances of mismatch deficiency or other targets for tyrosine kinase inhibitors. The development of methods for sequencing cell-free DNA should allow for broader and easier implementation of tumor genomic testing. Transcriptome-based expression signatures have become the standard of care in the management of early-stage estrogen receptor–positive breast cancers. These assays provide prognostic significance in the setting of adjuvant endocrine therapy and are predictive for benefit from adjuvant chemotherapy. Collectively, these developments underscore the contemporary reality that molecular testing is now part of the clinical management for the majority of patients with breast cancer.

scholarly journals Living with Advanced Breast Cancer among Ghanaian Women: Emotional and Psychosocial Experiences

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Adwoa Bemah Bonsu ◽  
Lydia Aziato ◽  
Joe Nat A. Clegg-Lamptey
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Health Care Providers ◽  
Emotional Reactions ◽  
Advanced Breast ◽  
Care Providers ◽  
Psychosocial Experiences ◽  
Cancer Management ◽  
Fear And Anxiety ◽  
Ghanaian Women

The purpose of this study was to explore the emotional and psychosocial experiences of Ghanaian women living with advanced breast cancer in the Kumasi metropolis. The study employed a qualitative exploratory descriptive design. Purposive sampling approach was used and data was saturated with 10 participants aged between 32 and 65 years. All interviews were audio-taped and transcribed. Data was analyzed concurrently based on the techniques of content analysis. Anonymity and confidentiality were ensured. Women experienced emotional reactions such as sadness, fear, and anxiety. Pain was severe and led to suicidal ideations. Women experienced lost hopes regarding their marriage, parenting, and work. They received support from their families, spouses, colleagues, health professionals, and spiritual leaders. Women coped by accepting the disease and surrendering to God and having the will to live. Five major themes described were emotional reactions, pain, lost hope, support, and coping. It was recommended that health care providers involved in breast cancer management should be trained to enhance effective and holistic care of women and their families. Also, patients with advanced disease should be given effective pain management and a multidisciplinary palliative care team should be instituted to care for the women.

scholarly journals Detection of circulating tumour cells in patients with Stage I–III breast cancer

2020 ◽  
Vol 24 (3) ◽  
pp. 107
Author(s):  
V. E. Ponomarev ◽  
O. A. Chernysheva ◽  
S. B. Polikarpova ◽  
E. A. Bogush ◽  
I. V. Vysotskaya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Advanced Breast Cancer ◽  
Conflict Of Interest ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Stage I ◽  
Cancer Management ◽  
Grade Of Malignancy

<p><strong>Aim.</strong> To increase the accuracy of risk stratification of breast cancer Stage I–III patients based on circulating tumour cell (CTC) determination.<br /><strong>Methods.</strong> Forty-seven breast cancer patients aged 28–77 years (median, 51 years) who were examined and treated at N.N. Blokhin National Medical Research Center of Oncology between 2015 and 2017 were enrolled in the study. The presence of CTCs was evaluated for all patients before treatment.<br /><strong>Results.</strong> CTCs were detected in 85.1% (40 out of 47) of the patients. The CTC detection rate in patients with early and locally-advanced breast cancer was approximately the same, 88.5% (23 of 26) and 81% (17 of 21), respectively (p = 0.7). Another important prognostic factor, which tended to be reliably linked to the frequency of CTC detection, was the grade of malignancy. Grade 2 tumours were more often observed in CTC-positive patients (77.5%) than in CTC-negative patients (22.5%, p = 0.06). None of the remaining clinical and morphological parameters were statistically associated with CTC positivity.<br /><strong>Conclusion.</strong> This study demonstrated that regardless of the clinical stage, CTCs were detected with approximately equal frequency in patients with early and locally-advanced breast cancer (88.5% and 81%, respectively). However, owing to the small number of patients studied, none of the differences were found to be statistically significant. Nevertheless, investigations on the relationship between the presence of CTCs, molecular-biological subtypes and grade of malignancy are important to evaluate their use as independent prognostic factors. Further studies are needed to assess the use of CTCs as an additional criterion or prognostic factor in breast cancer management.</p><p>Received 17 September 2020. Accepted 25 September 2020.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions</strong><br />Conception and design: S.B. Polikarpova, N.N. Tupitsyn, O.A. Chernyshova, V.E. Ponomarev, E.A. Bogush, I.V. Vysotskaya, V.Yu. Kirsanov<br />Data collection: V.E. Ponomarev, O.A. Chernyshova<br />Data analysis: V.E. Ponomarev, O.A. Chernyshova<br />Drafting the article: V.E. Ponomarev, O.A. Chernyshova<br />Critical revision of the article: S.B. Polikarpova, N.N. Tupitsyn, E.A. Bogush, I.V. Vysotskaya, V.Yu. Kirsanov<br />Final approval of the version to be published: V.E. Ponomarev, O.A. Chernysheva, S.B. Polikarpova, E.A. Bogush, I.V. Vysotskaya, V.Yu. Kirsanov, N.N. Tupitsyn</p>

scholarly journals Does Multidisciplinary Care Enhance the Management of Advanced Breast Cancer?: Evaluation of Advanced Breast Cancer Multidisciplinary Team Meetings

2010 ◽  
Vol 6 (6) ◽  
pp. 294-300 ◽  
Author(s):  
Jacquie Chirgwin ◽  
Melinda Craike ◽  
Christine Gray ◽  
Kathy Watty ◽  
Linda Mileshkin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Multidisciplinary Team ◽  
Multidisciplinary Approach ◽  
Multidisciplinary Care ◽  
Standard Of Care ◽  
Advanced Breast ◽  
Team Meetings ◽  
Cancer Management ◽  
Multidisciplinary Team Meetings

In recent years, the multidisciplinary approach has become the standard of care in cancer management. However, evidence demonstrating the value of multidisciplinary care and team meetings remains scarce.

Sign in / Sign up

Export Citation Format

Share Document